VAR2CSA-Based CAR Targeting pl-CSA for Solid Tumor Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current CAR-T cell technologies face challenges such as limited specificity for targeting various types of tumors, severe toxic side effects, and difficulty in effectively treating solid tumors due to immune suppression and tumor microenvironment barriers.

Innovation Solution

A chimeric antigen receptor (CAR) that utilizes the malarial protein VAR2CSA or its recombinant protein (rVAR2) to target placental-like chondroitin sulfate A (pl-CSA) on tumor cells, enabling broad targeting of multiple tumor types while minimizing toxicity by only acting in the presence of VAR2CSA protein.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If CAR-T cells are designed to target multiple tumor types, then the versatility and applicability increase, but the specificity and risk of off-target effects increase

Engineering Contradiction:

Improvetumor targeting versatilityVSAvoidoff-target toxicity

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces VAR2CSA protein or its recombinant form rVAR2 as an intermediary component in the CAR structure. This intermediary specifically binds to placental-like chondroitin sulfate A (pl-CSA) which is expressed on multiple tumor types, enabling broad targeting while maintaining specificity through the unique VAR2CSA-pl-CSA interaction mechanism

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The CAR-T cells are designed with VAR2CSA-based recognition domain that can universally target multiple different tumor types through the common pl-CSA antigen, achieving multi-functionality without requiring separate CAR designs for each tumor type

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Adaptability or versatility

If CAR-T cells are designed to target solid tumors, then the treatment scope expands, but the effectiveness is reduced due to immune suppression and microenvironment barriers

Engineering Contradiction:

Improvesolid tumor treatment capabilityVSAvoidtreatment effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent modifies the CAR structure by incorporating VAR2CSA protein domains that are specifically optimized for solid tumor targeting. The recombinant protein rVAR2 with specific domain configurations enables the CAR-T cells to effectively penetrate and function within the solid tumor microenvironment, overcoming physical and immunological barriers

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If CAR-T cells are designed with high specificity for tumor antigens, then the toxicity to normal cells is reduced, but the applicability to different tumor types is limited

Engineering Contradiction:

Improvetoxicity to normal cellsVSAvoidapplicability to different tumor types

Core Design Contradiction:

Object-affected harmful factorsVSAdaptability or versatility

Solution Approach 1:

The VAR2CSA protein serves as a specific intermediary that binds to pl-CSA on tumor cells with high affinity and specificity. This specific binding mechanism ensures that CAR-T cells only activate and exert cytotoxic effects when VAR2CSA binds to its target, minimizing off-target toxicity while the widespread expression of pl-CSA across multiple tumor types enables broad applicability

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The CAR-T cells equipped with the VAR2CSA-based CAR demonstrate enhanced specificity and efficacy in targeting a wide range of tumor cells, reducing toxic side effects by ensuring activity only in the presence of tumor-specific antigens, and potentially overcoming immune suppression in solid tumors.

Implementation Method 1

VAR2CSA can targeted and bind to proteoglycan modified by a placental-like chondroitin sulfate (CS) glycosaminoglycan (GAG) chain (also known as placenta-like chondroitin sulfate A, abbreviated as pl-CSA)

Methodology Applied

Scientific EffectProtein-carbohydrate binding:

Data Source

PatentUS12221475B2Chimeric antigen receptor and application thereof

Publication Date: 2025.02.11 GUANGZHOU LAMGENE BIOMEDICAL TECHNOLOGY CO LTD

AI summary

Provided are a chimeric antigen receptor and an application thereof; said chimeric antigen receptor contains a domain which identifies any one of, or a combination of at least two of, the malarial protein VAR2CSA, a protein tag on malarial protein VAR2CSA, or a compound capable of labeling the malarial protein VAR2CSA. The chimeric antigen receptor can identify the VAR2CSA protein or the recombinant protein (rVAR2) of any one of, or at least two of, the domains of the VAR2CSA protein which can bind to placental-like chondroitin sulfate A (pl-CSA). The VAR2CSA protein or rVAS2 protein is capable of targeting several different types of tumor cells by means of binding to the pl-CSA on the surface of the tumor cell.